BTIG analyst Marie Thibault maintained a Buy rating on Vapotherm (VAPO – Research Report) on June 24 and set a price target of $7.00. The company’s shares closed last Friday at $3.16, close to its 52-week low of $2.46.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of 6.2% and a 27.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.
The word on The Street in general, suggests a Hold analyst consensus rating for Vapotherm with a $4.83 average price target.
The company has a one-year high of $31.87 and a one-year low of $2.46. Currently, Vapotherm has an average volume of 450.8K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VAPO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. It offers Hi-VNI Technology, a product which delivers noninvasive ventilator support by providing heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. Its products include Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, Precision Flow Heliox, Vapotherm Transfer Unit 2.0, Q50 compressor, Disposable Patient Circuit, Nitric Oxidie Disposable Patient Circuit, Nasal Cannulas, Tracheostomy Adapter and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.
Read More on VAPO: